Pediatrix Medical Group (MD) reports earnings tomorrow: what to expect

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Thursday morning. Here’s what to look for.

Pediatrix Medical Group beat analysts’ revenue expectations last quarter, reporting revenues of $487.8 million, up 4% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and full-year EBITDA guidance meeting analysts’ expectations.

Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Pediatrix Medical Group’s revenue to be flat year on year, improving from the 3.6% decrease it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Pediatrix Medical Group has a history of exceeding Wall Street’s expectations.

Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 14.5%, missing analysts’ expectations by 7.1%, and Elevance Health reported flat revenue, topping estimates by 3.1%. Elevance Health traded up 1.2% following the results.

Read our full analysis of The Ensign Group’s results here and Elevance Health’s results here.

There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 3.6% on average over the last month. Pediatrix Medical Group is up 11.2% during the same time and is heading into earnings with an average analyst price target of $26.33 (compared to the current share price of $28.84).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.